Objective: To compare the effects of different prophylactic iron doses on the growth and nutritional status of non-anemic infants.
Introduction
Iron deficiency anemia is a highly prevalent nutritional disorder in many populations worldwide. Children in the first 2 years of life are considered risk groups. 1 The main consequences of childhood anemia are the probably irreversible deficits in mental and psychomotor development. 2 However, other effects are also mentioned, such as behavioral changes, 2 decreased resistance to infections, 3 and reduced growth processes. 4 Iron supplementation is an essential strategy for anemia prevention in areas where its prevalence is high. 5 In the literature, several prophylactic iron supplementation regimes have been proposed to prevent anemia in the first years of life, such as those by the World Health Organization, 1 Pediatric committees, 6, 7 and by specific federal departments, such as the Brazilian Ministry of Health. 8 The real advantages and disadvantages of using these different prophylactic iron supplementation regimes have been poorly investigated. In addition, there is a paucity of studies on the effect of these regimes on specific groups such as non-anemic or non-iron-deficient infants. Iron is essential to many biochemical processes, such as electron transfer reactions, and regulation of cell growth and differentiation. On the other hand, it is also a potent cellular pro-oxidant, and its excess may impair many cellular processes. 9 There is controversy over whether iron supplementation affects infants' growth. Studies have yielded different results, ranging from absence of effects 10, 11 to advantages 12, 13 and disadvantages. 14, 15 The possible effect of iron supplementation on growth can be caused by alterations in the immune system, which result in high or low morbidity risk. However, there is no consensus on the association between iron supplementation and the incidence of morbidity among children. 3, 16, 17 It has been argued that anemic children seem to respond more positively to iron supplementation. Nevertheless, the effects of iron supplementation on the growth of non-anemic or non-iron-deficient children remain inconclusive. 18 The risks and benefits of iron supplementation apparently vary according to initial hemoglobin levels and to iron nutritional status markers. The beneficial effects of iron supplementation have been shown primarily in anemic children. 9 It is known that universal supplementation with prophylactic iron doses can reach a great number of non-anemic infants. However, its effects on growth are still controversial.
Therefore, the purpose of this study was to compare the effects of different prophylactic iron doses (administered on a daily or weekly basis) on the growth and nutritional status of non-anemic infants.
Methods
This a prospective, randomized study of prophylactic inter- participating in the study were interviewed. Inclusion criteria were: (1) age 5.0 to 6.9 months; (2) infants living in the urban area; (3) full-term, single-birth babies; (4) birth weight ≥ 2,500 g; (5) mother's age > 19 years; (6) absence of neonatal intercurrent events, of congenital anomalies and of chronic diseases; (7) no previous iron supplementation; (8) non-exclusive breastfeeding; and (9) capillary hemoglobin ≥ 11 g/dL (non-anemic infants).
In the screening phase, the capillary hemoglobin of 213 infants who met the first eight criteria of inclusion was measured. The 78 infants diagnosed with anemia (hemoglobin < 11 g/dL) (36.6%) were referred for treatment and excluded from the study, whereas 135 non-anemic infants (hemoglobin ≥ 11 g/dL) (63.4%) were randomly included in the three groups of prophylactic intervention with iron supplements. For inclusion in the study, a questionnaire containing information about the infant (birth conditions, socioeconomic background and breastfeeding history) was answered by parents. Exclusive breastfeeding time was defined as the age (in days) during which the infant ingested only breast milk, without water or tea. Predominant breastfeeding time was defined as the age during which the infant was predominantly fed breast milk, but was also given water, teas or fruit juice. 19 During the intervention period, food intake was evalu- 
Results
One hundred and thirty-five infants were included in the study (n = 51 in group I, n = 42 in group II and n = 42 in group III). Of these, 114 completed the intervention and 21 were lost to follow-up. The reasons for these losses were: patient withdrawal (n = 7); supplement intolerance (n = 6); non-compliance, that is, the supplement was not supplied until the first visit after its use was recommended (n = 4); moving out of town (n = 2); and anemia diagnosed during the study by an exam requested by physicians (n = 2). The sample loss did not differ statistically between the studied groups (n = 12 in group I, n = 6 in group II and n = 3 in group III) (p = 0.091).
The characteristics evaluated at admission did not differ between the supplemented groups. Besides, there were no statistical differences in daily intake of energy and nutrients during the supplementation period (Table 1) .
Before supplementation, nutritional deficits (< -2 z score) in the total population were 4.4% (n = 5) for weight/age, 2.6% (n = 3) for length/age and 5.3% (n = 6) for weight/length. By the end of the supplementation, the population presented deficits of 2.6% (n = 3) in weight/age, 3.5% (n = 4) in length/ age and 3.5% (n = 4) in weight/length. When the mean anthropometric measurements were compared before and after supplementation, there was a significant increase in weight/age (initial mean = 0.06±1.07 versus final mean = 0.15±1.15; p = 0.029) and in weight/length (initial mean = 0.05±1.08 versus final mean = 0.18±1.15; p = 0.017), but no statistically significant change in length/age was observed (initial mean = 0.15±1.07 versus final mean = 0.11±1.09; p = 0.297).
Initial values of weight, length and of weight/age, length/ age and weight/length did not differ statistically between groups. After supplementation, groups I, II and III gained 1.20, 1.26 and 1.37 kg in weight and 5.15, 5.22 and 5.61 cm in length, respectively (values of p > 0.05). In the evaluated groups, final means of anthropometric indices did not differ from the initial ones, except for weight/age in group III and weight/length in group II, which showed a significant increase.
During the study period, weight gain, length gain and increases in anthropometric indices did not differ statistically between groups (Table 2) .
Supplemented groups did not differ as to the occurrence of morbidity during the four monthly home visits. Besides, no statistically significant differences were found among groups concerning the occurrence and duration of diarrhea, fever and symptoms of respiratory diseases, such as cough, coryza, nasal congestion and wheezing (Table 3) .
Discussion
In the present study, the groups of non-anemic infants supplemented with different prophylactic iron doses did not differ in terms of growth and nutritional status. However, infants from the group with intermittent supplementation (group III) and from the group treated with a higher daily dose (group II) showed significant increase in weight/age and weight/length z scores, respectively. Even though the iron doses markedly differed in terms of content and frequency, the groups with higher doses (group I and II) did not show differences regarding weight gain, length gain and anthropometrical indices (weight/age, length/age and weight/length) in comparison with the group who received lower doses (group III). According to these results, neither content nor frequency of prophylactic iron doses influenced the growth of non-anemic infants.
Growth in iron-supplemented infants -da Silva DG et al.
Consistently with these results, other studies also did not find differences between the effects of intermittent and daily iron supplementation on the nutritional status of infants. 23, 24 However, a study with school-aged Thai children demonstrated that, after 16 weeks of supplementation, the group supplemented with a weekly dose of iron (60 mg/week) showed higher length gain comparatively to the group supplemented with a daily dose (60 mg/day). 25 There are few studies about the benefits and risks of daily iron supplementation in non-anemic, non-iron-deficient infants. In Indonesia, a study with non-iron-deficient infants revealed, after 4 months, that the group supplemented with 3 mg of iron/kg/day had a lower weight gain than the placebo group. 14 In this Indonesian study, a higher iron dose (therapeutic dose) was administered to children without iron deficiency. Such practice is rarely verified in universal iron supplementation programs, which normally use lower doses (prophylactic doses). In a study with breast-fed infants supplemented with prophylactic doses of iron (1 mg/kg/ day), distinct results were obtained in evaluated populations.
In Sweden, supplementation between the fourth and the ninth months of age was related to a lower length gain and to a lower head circumference. In a study performed in Honduras, where children presented poor iron nutrition, supplementation between the fourth and sixth months had a negative effect only on non-anemic infants. 15 The authors warned against the risk of adverse effects on health in the long run caused by daily iron supplementation in infants younger than 6 months, due to the immature regulation of iron metabolism.
With regard to the groups assessed in the present study, group I, which received the same iron dose (1 mg/kg/day) as in the previously mentioned work, 15 showed similar gains in weight and length in comparison with the other groups. A recent systematic review concluded that iron supplementation did not affect the weight and length of infants. 10 In addition, the study showed no association between initial hemoglobin levels and the effects of supplementation on growth.
It is estimated that the prevalence of iron deficiency anemia increases as the prevalence of nutritional anemias increases. 1 Thus, considering the high prevalence of anemia (36.6%) verified in the screening phase of the study, a great number of the selected non-anemic infants supposedly had some iron deficiency before the intervention. In addition, it is unlikely that the ingestion of prophylactic iron doses has caused impaired the growth or the nutritional status of the evaluated infants, because during the supplementation period there were increases in weight/age and weight/length of the general population. Length/age did not show significant changes after the supplementation.
There is no evidence about which mechanisms could explain how iron supplementation can interfere in growth.
However, indirect effects might be involved. The benefits of iron supplementation on growth could be justified by increased appetite and consequently higher food intake, 13 or even by strengthening of the immune system, with positive consequences such as a reduction in the incidence of morbidity. 3 On the other hand, some probable negative effects of iron supplementation are mentioned in the literature, such as competitive inhibition of other nutrients by iron; for example, zinc, which has a direct effect on growth processes. The authors of a recent review claimed that there is a lack of evidence linking iron supplementation to reduced zinc serum levels. 26 Another hypothesis is that iron could enhance vulnerability to infections and, consequently, impair growth. The findings about this association are controversial. 16, 17 There is also the hypothesis that excess body iron, due to its pro-oxidant characteristic, could stimulate the formation of free radicals, damaging several metabolic processes, including growth. 9, 15 During supplementation, the groups did not differ in terms of morbidity and duration of diarrhea, fever, cough, coryza or nasal congestion and wheezing. On the other hand, monthly evaluations showed great morbidity in this population: more than half of the infants presented some kind of morbidity. Also, symptoms of respiratory infections, such as cough, coryza or nasal congestion and wheezing, were reported.
According to Oppenheimer, 16 there is no evidence that iron supplementation is associated with increased morbidity in non-endemic areas of malaria. However, in endemic areas, therapeutic iron supplementation can increase the risk of infectious diseases. Gera & Sachdev 17 concluded that iron supplementation did not affect the general incidence of infections, but that it increased the risks for diarrhea. The authors asserted that such fact would not have an impact on public health, because of the little difference in the incidence of diarrheal episodes. In another study, prophylactic iron supplementation showed reduced risk of diarrhea in anemic individuals but increased the risk in non-anemic ones. 15 The existence of many confounding factors, which affect both the immunity and the iron nutritional status of populations, can hinder the interpretation of results of intervention studies.
Generally, infants showed improvement in weight/age and weight/length indices during supplementation in the present study. The general monthly mean weight gain (337.7±127.6 g) was above the World Health Organization recommendation, which is around 313 g (2006). 22 As to length/age, nutritional status was maintained after supplementation. Monthly mean length gain (1.33±0.27 cm) was somewhat below recommendation (1.46 cm).
A study involving Indonesian, Peruvian, Vietnamese and South African infants showed that iron and/or micronutrient supplementation did not control growth deficits in the first
year of life. 27 The benefits of iron supplementation on children's growth are likely to be more evident in populations with severe nutritional problems. Nutritional status of anemic populations also seems to benefit from iron supplementation. 28 With regard to dietary intake, 61.4% (n = 70) of the infants showed adequate energy intake compared to the estimated energy requirement. 29 However, considering that 80%
were being breast-fed, it is believed that daily variations in breast milk intake may have guaranteed more adequate energy ingestion. It should be pointed out that the amount of breast milk ingested was not directly assessed, but rather estimated, based on a predictive formula. 20 Probably, this procedure caused the total intake of breast milk to be underestimated.
Certainly, a methodological limitation of the present study is the absence of a placebo group. This prevents us from drawing accurate conclusions about the effect of iron supplementation on the nutritional status of non-anemic children. It is still worthy mentioning that the detection of effects on growth and on nutritional status generally requires a greater sample size than the one used in this study. However, this is one of the few studies that compared the effect of different prophylactic iron doses on infants in the first year of life, as well as the critical period concerning iron requirements and physical development.
The conclusion is that different prophylactic iron doses did not show a differential effect on the growth and nutritional status of non-anemic infants. Besides, the growth of infants who received daily iron supplements (1 or 2 mg/kg/day) was similar to that of infants given intermittent iron doses (25 mg/week). Other studies are necessary in order to confirm these results and to investigate the effect of prophylactic iron supplementation on anemic and non-anemic children.
